Securing the Future PortalHealth and Social Care PortalEfficiency and Productivity Portal

European Medicines Agency confirms positive benefit-risk balance of Protelos/Osseor, but recommends new contraindications and revised warnings

Medicines no longer recommended for use in immobilised patients or patients with venous thromboembolism (VTE); update of warnings regarding serious skin reactions.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has finalised a review of Protelos and Osseor (strontium ranelate), from Les Laboratoires Servier. The Committee concluded that these medicines remain an important treatment for women with osteoporosis, but that changes to the prescribing advice are necessary to better manage associated risks.

Protelos and Osseor are indicated for the treatment of osteoporosis in postmenopausal women to reduce the risk of broken bones in the hip and spine.

The review of Protelos and Osseor was started following the publication of a study in France identifying 199 severe adverse reactions reported with these medicines from January 2006 to March 2009. Around half of these were VTE events, and about a quarter related to skin reactions.

VTE and severe skin reactions are known risks of these medicines and have been kept under close review by the CHMP. The risk of VTE was identified in clinical trials and the risk of severe skin reactions, such as DRESS (drug rash with eosinophilia and systemic symptoms), SJS (Stevens-Johnson syndrome) and TEN (toxic epidermal necrolysis) had been reported post marketing. Information on these risks had been included in the product information as warnings or listed as reported side effects.

The CHMP has reviewed all available data on the safety of Protelos and Osseor. The data show that the risk of VTE is higher in patients with a history of VTE, as well as in patients who are temporarily or permanently immobilised. The number of cases of VTE in elderly patients is also shown to be higher with Protelos and Osseor compared with placebo.

The data also show that the incidence rate of serious skin reactions such as DRESS, SJS and TEN is low and no possible mechanism of action has been identified so far. Because the best results in managing these conditions come from early diagnosis and immediate discontinuation of any suspect drug, it is very important that doctors and patients are alert to the time-to-onset and signs and symptoms of these conditions.

Written by Scott Buckler
Friday, 16 March 2012 11:11

Add comment


Security code
Refresh

Most Read Tags

Interviews

The Govtoday Debate

Karen Jennings, Assistant General Secretary, UNISON

FORTHCOMING EVENTS / POST-EVENT DEBATES

GovToday Limited Peter House Oxford Street Manchester M1 5AN

Copyright © 2012 Govtoday. All Rights Reserved.